The development and review timelines for new drugs are critical in addressing the immediate medical needs of patients with serious conditions. In this context, the United States Food and Drug Administration (FDA)’s Fast Track and Accelerated Approval pathways play a pivotal role. These regulatory f
In recent years, a noticeable shift has emerged in the realm of clinical cancer research, with pharmaceutical companies now playing a dominant role in funding and conducting trials. This transformation is evident in the stark contrast between industry and federal sponsorships. Between 2018 and
The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has
The landscape of Alzheimer’s disease (AD) diagnosis and treatment is undergoing a significant transformation thanks to the groundbreaking Simoa® technology by Quanterix. This ultra-sensitive immunoassay platform is reshaping how biomarkers are identified and validated, offering new possibilities fo
The quest for faster and more efficient protein structure prediction has taken a significant leap forward with the advent of MassiveFold, a new iteration of AlphaFold designed for parallel processing. Within the realm of molecular biology and drug discovery, the speed and accuracy of protein
A new partnership between two powerhouses in the pharmaceutical industry promises substantial advancements in drug discovery and development. Novartis, one of the largest pharmaceutical companies globally, will pay Schrödinger $150 million upfront to utilize its advanced computing tools and
